How can our biologics drug development program move forward from DNA-to-IND faster?

Our integrated DNA-to-IND programs support a full range of modalities – from monoclonal antibodies (mAbs) to complex biologics like antibody-drug conjugates (ADCs), antibody oligonucleotide conjugates (AOCs) and bispecifics.

When appropriate, you can transfer your established cell line or process, at any development stage and we’ll work with you to achieve your next milestone faster.

Fully integrated technology platforms and robust development methods are the key to delivering a faster DNA-to-IND approach. Abzena’s enhanced GMP-ready cell line development platform, AbZelectPRO™, increases productivity, titers, yields, and overall performance.